Latest

2 stories

Hide weekly roundups

Wednesday, September 30

Clinical readoutEupraxia Pharmaceuticals Inc.

Eupraxia reports 52-week data from highest dose cohort of EP-104GI in RESOLVE trial

The company said 9 of 14 patients across cohorts 5-9 remained in clinical remission at 52 weeks after a single dose, with no treatment-related serious adverse events reported.

SEC filing

Thursday, August 13

Clinical readoutEupraxia Pharmaceuticals Inc.

Eupraxia reports new odynophagia data from Phase 1b/2a RESOLVE trial in EoE

The company said swallowing pain and difficulty both dropped substantially in a subset of patients through 52 weeks, with no serious safety signals reported.

SEC filing